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Figure 2. Coronary arteriograms I week after infarction. Top,
Left coronary artery, in left oblique view, showing total occlusion
of the left anterior descending artery (x) after the diagonal branch
(D). Bottom, Right coronary artery, in right oblique view, is
normal; a large posterior descending branch (PDA) extends up to
the cardiac apex. LCX = left circumflex coronary artery.
viously, there appears to be a proximal indentation in the right
coronary artery that could represent atherosclerotic plaque. Such
a large posterior descending artery would suggest, in our experi-
ence, that the left anterior descending artery was not large or
extensive and probably was not responsible for the inferior wall
ST changes when it became occluded.
Singh suggests that the events described may have resulted
from' 'reflex spasm of resistance vessels in the right coronary artery
distribution." An equally reasonable and, to us, more appealing
hypothesis is that this patient may have had spasm of both the
proximal left anterior descending artery, leading to its occlusion,
and of the proximal right coronary artery (perhaps at the site of
the indentation seen on the arteriogram), leading to the transmural
inferior wall ischemia observed, that resolved after treatment with
nitroglycerin. Indeed, perhaps the patient's prior symptoms, which
led to earlier coronary arteriography, were the result of spasm as
well. Spasm may even have provoked atherosclerotic lesions, a
possibility suggested by some of us in the past (I).
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Adenosine in Atrial Arrhythmias
In patients treated with adenosine for supraventricular tachycardia
(I) we found, as did Di Marco et al. (2) in their recent study, that
few side effects were volunteered. When I was a volunteer for a
pilot study of the heart rate effects of intravenous adenosine more
side effects came to light. Subsequently it has become apparent
that chest, abdominal and neck discomfort (3) are common but
transient adverse effects of intravenous adenosine.
I am surprised at how few patients reported dyspnea in the
study of Di Marco et al. We found that the "dyspnea" is, in fact,
respiratory stimulation (3), and in 29 subjects studied, objective
respiratory stimulation was a consistent finding (unpublished ob-
servations). The effects of intravenous adenosine on bronchial tone
in normal subjects (unpublished data) are small and are unlikely
to explain this effect. Di Marco et al. discuss dipyridamole as a
relative contraindication to intravenous adenosine. In patients tak-
ing dipyridamole the effective dose of adenosine (1.0 :±: 0.52 mg)
was significantly less than the effective dose (8.8 :±: 2.6 mg) in
patients not taking the drug (I). We suggested that the initial dose
of adenosine should not exceed I mg in patients taking dipyrid-
amole to avoid the risk of possible severe bradycardia. Another
reason to exercise caution in the use of intravenous adenosine is
concurrent asthma. Our preliminary observations suggest that in-
travenous adenosine produces more marked bronchoconstriction
than in normal subjects (unpublished data), which is consistent
with data reported for inhaled adenosine (4).
Like Di Marco et aI., we found no adverse interactions with
antiarrhythmic drugs (I). Despite the subjective side effects that
intravenous adenosine produces, I agree with Di Marco et al. that
intravenous adenosine has significant potential as a short-term
treatment for certain supraventricular arrhythmias.
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Reply
We agree that transient dyspnea is common after injection of doses
of adenosine sufficient to produce change in sinus rate at rest.
However, in comparison studies, we (1) have shown that the dos-
age required to terminate paroxysmal supraventricular tachycardia
in the same patient is usually lower and thus the sensation of
dyspnea is much less common.
The effects of adenosine on respiration are still incompletely
understood. Some authors (2) have concluded that adenosine is a
central respiratory depressant rather than a stimulant as proposed
by Watt. In our experience, most patients with severe asthma are
receivmg a methylxanthine. Because methylxanthines in thera-
peutic doses block the electrophysiologic effects of adenosine, we
have not treated any such patients. Two of our patients had a
history of mild asthma that did not require long-term prophylactic
therapy; neither reported any unusual side effects from adenosine.
Finally, the unusually rapid elimination of adenosine after injection
is due to rapid cellular uptake by a mechanism blocked by dipyr-
idamole. In our study we excluded patients receiving this agent
because we anticipated that markedly lower dosage requirements
would be observed. Because alternative forms of therapy are usu-
ally available, one might question whether adenosine should be
the drug of choice in patients receiving dipyridamole.
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